Phase 4 N=210 Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving DAS28 Low Disease Activity at Week 12 — 21.2; 33.0 percentage of participants — p=0.055
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=194 Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study
Rheumatoid Arthritis
Primary: Clinical Disease Activity Index (CDAI) Remission (≤2.8) at Both Week 20 and Week 24 — 18.8; 6.1 percentage of subjects
N/A N=353 Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy
Rheumatoid Arthritis
Primary: Mean 48-week Change in DAS28 — -2.12; -2.29 units on a scale
Phase 3 N=131 Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study
Rheumatoid Arthritis
Primary: Percentage of Subjects Reporting At Least One Treatment-emergent Adverse Event (TEAE) During The Study Period — 70.8 percentage of participants
Phase 3 N=886 A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)
Rheumatoid Arthritis
Primary: Percentage of Participants Experiencing at Least One Serious Adverse Event (SAE) During the 24 Week Treatment Period — 5.8; 8.0; 8.4 Percentage of Participants
Phase 4 N=54 A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs
Rheumatoid Arthritis
Primary: Percent Change From Baseline to Week 12 in Synovitis Measured by Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic…
Phase 3 N=288 MSB11022 in Moderate to Severe Rheumatoid Arthritis
Moderate to Severe Rheumatoid Arthritis
Primary: Percentage of Participants With Treatment-emergent Adverse Events of Special Interest (AESI) — 4.2; 5.5 Percentage of Participants
Phase 3 N=527 A Moderate to Severe Rheumatoid Arthritis Study
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response - Placebo Versus Baricitinib 4 mg — 27.3; 55.4 Percentage of Participants…
Phase 3 N=65 A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Safety: Percentage of Participants With Treatment Emergent Adverse /Serious Adverse Events — 90.8; 9.2; 52.3 percentage of participants
Phase 3 N=1,162 A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 24 — 15.0; 31.9; 44.8; 38.7 Percentage of participants — p=<0.0001
Phase 2 N=326 A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Score at Day 85 — 5.78; 5.73; 5.91; 5.67 units on a scale — p=<0.001
Phase 4 N=489 Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening
Rheumatoid Arthritis
Primary: Percentage of Participants Who Remained in Low Disease Activity (LDA) (Disease Activity Score in 28 Joints-erythrocyte Sedimentation Rate [DAS28-ESR] <3.2) at Week 52…
Phase 3 N=684 A Study in Moderate to Severe Rheumatoid Arthritis Participants
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20) — 39.5; 65.9; 61.7 percentage of participants — p=0.001
Phase 3 N=1,196 A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
Primary: Percentage of Participants With American College of Rheumatology-ACR20 Response — 27.0; 50.6; 56.3 Percentage of participants — p=<0.0001
N/A N=18 Ultrasound Efficacy in Moderate Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Low Synovitis Scores — 1 Participants
Phase 3 N=105 A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Improvement of Anemia at Week 4 Assessed as Change From Baseline in Hemoglobin — 0.40 g/dL
Phase 3 N=604 MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) — -3.53; -3.54 score on a scale
Phase 4 N=234 An Efficacy and Safety Study of Infliximab in Participants With Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Percentage of Participants Achieving American College of Rheumatology Score 20 Percent (ACR20) Response — 63.46; 76.15 Percentage of participants
Phase 2 N=48 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)
Rheumatoid Arthritis (RA)
Primary: Change From Baseline to Week 12 in Disease Activity Score (DAS) 28 (C-reactive Protein [CRP]) — -2.51; -2.65 score on a scale — p=0.022
Phase 4 N=95 A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants Reporting Any Adverse Event - Overall Summary of Events — 8.4; 0; 38.9; 45.3 percentage of participants
Phase 2 N=248 Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving a Successful Composite Clinical Response According to the Criteria for American College of Rheumatology 20% Response (ACR20) — 48.4…
Phase 3 N=1,063 Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: American College of Rheumatology 20% (ACR20) Response at Week 12 — 51.1; 25.9 percentage of subjects
Phase 3 N=185 A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate
Rheumatoid Arthritis
Primary: Change in Magnetic Resonance Imaging (MRI) Erosion Score From Baseline to Week 24 — 0.13; 0.39; 1.33 Units on a scale
Phase 2 N=60 Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Number of Treatment-emergent Adverse Events in the ABX464 Treated Patients Versus Placebo — 18; 18; 14 Participants
Phase 4 N=9 Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Disease Activity Score for 28-joint Counts (DAS28) — 5.7; 4.3 score on a scale
Phase 4 N=694 Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Double Blind Phase: Change From Randomization in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (Erythrocyte Sedimentation Rate [ESR]) at Week 48…
Phase 2 N=254 Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients
Rheumatoid Arthritis
Primary: ACR Efficacy Criteria — 63; 57; 57; 61 participants
Phase 3 N=77 A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate
Rheumatoid Arthritis
Primary: Change From Week 12 (Randomization) to Week 24 in DAS28 — 0.17; -0.16 score on a scale — p=0.188
Phase 3 N=656 A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24 — 60.9; 31.5 Percentage of patients — p=<0.001
Phase 4 N=203 RESTART C0168Z05 Rheumatoid Arthritis Study
Rheumatoid Arthritis
Primary: Percent of Patients Who Achieved a EULAR (The European League Against Rheumatism) Response at Week 10 — 49.7 Percentage